Thyrocare Technologies Ltd reported a strong performance for the July–September quarter, with net profit rising 79% year-on-year to ₹48 crore, supported by higher test volumes and improved efficiency.
Revenue climbed 22% to ₹216.5 crore from ₹177.4 crore a year earlier, while EBITDA grew 47.5% to ₹71.3 crore. Operating margins expanded to 32.9% from 27.2%.
In the pathology segment, franchise revenue grew 20% year-on-year, while partnership revenue recorded a robust 35% increase, underscoring continued expansion in both core and allied services.
The diagnostics chain processed 53.3 million tests during Q2 FY26, a 21% year-on-year growth, reaffirming its position as India’s largest diagnostic test volume processor.
The company remains debt-free on a consolidated basis, holding net cash and equivalents of over ₹190 crore, including short-term investments. During the first half of FY26,
Thyrocare also added four new laboratories in Vijayawada, Bhagalpur, Roorkee, and Kashmir, further strengthening its regional presence and expanding access to diagnostic services.
Also Read: Bonus Share Alert: Healthcare services provider announces first ever free issue for shareholders
Alongside its earnings, Thyrocare announced an interim dividend of ₹7 per share, with the record date set for October 24, 2025.
The company also approved a 2:1 bonus issue, marking the first in its history and underscoring its commitment to shareholder value creation.
Ahead of the results, Thyrocare shares closed at ₹1,264.60 on the NSE, up 0.24%.
First Published: Oct 14, 2025 4:53 PM IST
